Source: Contract Pharma

Baliopharm: Alvotech Acquires Baliopharm

Baliopharm to be rebranded as Alvotech Germany

Est. Annual Revenue

$100K-5.0M

Est. Employees

1-25

Founder & CEO

Andreas Herrmann

CEO Approval Rating

84/100

Baliopharm develops and commercializes biological therapies for the treatment of immune-mediated inflammatory diseases and cancer.